Management of viral infections in immunocompromised cancer patients

Swiss Medical Weekly

Volumn 132, Issue 27-28, 2002, Pages 374-378

  Reusser, Pierre ^a  

^a Hopital Regional   (Switzerland)

Author keywords

Antiviral drug resistance; Antiviral prophylaxis; Antiviral therapy; Immunocompromised cancer patients; Stem cell transplantation; Virus infection

Indexed keywords

ACICLOVIR; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; HERPES ZOSTER IMMUNOGLOBULIN; INACTIVATED VACCINE; OSELTAMIVIR; PLECONARIL; SIALIDASE INHIBITOR; VALACICLOVIR; VARICELLA ZOSTER VACCINE; ZANAMIVIR;

CANCER PATIENT; CHICKENPOX; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES ZOSTER; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; LEUKEMIA; PICORNAVIRUS; PRACTICE GUIDELINE; PROPHYLAXIS; SHORT SURVEY; STEM CELL TRANSPLANTATION; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION; VIRUS RESISTANCE;

EID: 0037072213     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (36)

1. Aquino VM, Farah RA, Lee ME, Sandler ES. Disseminated coxsackie A9 infection complicating bone marrow transplantation. Pediatr Infect Dis J 1996;15:1053-4.
2. Whimbey E, Champlin RE, Couch RB, Englund JA, Goodrich JM, Raad I, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infeet Dis 1996;22:778-82.
3. Reusser P. Management of viral infections. In: Klastersky J, Schimpff SC, Senn H-J, eds. Supportive Care in Cancer: A Handbook for Oncologists. 2nd Ed. New York: Marcel Dekker, Inc.; 1999. p. 87-112.
4. Nguyen Q, Estey E, Raad I, Rolston K, Kantarjian H, Jacobson K, et al. Cytomegalovirus pneumonia in adults with leukemia: An emerging problem. Clin Infect Dis 2001;32:539-45.
5. Jefferson T, Demicheli V, Deeks J, Rivetti D. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev 2000;2:CD001265.
6. Rotbart HA, Webster AD, for the Pleconaril Treatment Registry Group. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis 2001;32: 228-35.
7. Nichols WG, Corey L, Gooley T, Drew WL, Miner R, Huang M-L, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: Risk factors, correlation with DNA load, and outcomes. Blood 2001;97:867-74.
8. Preiser W, Brauninger S, Schwerdtfeger R, Ayliffe U, Garson JA, Bri NS, et al. Evaluation of diagnostic methods for the detection of cytomegalovirus in recipients of allogeneic stem cell transplants. J Clin Virol 2001;20:59-70.
9. Bustamante CI, Wade JC. Herpes simplex virus infection in the immunocompromised cancer patient. J Clin Oncol 1991;9: 1903-15.
10. Balfour HH Jr. Antiviral drugs. N Engl J Med 1999;340:1255-68.
11. Feldman S, Lott L. Varicella in children with cancer. Impact of antiviral therapy and prophylaxis. Pediatrics 1987;80:465-72.
12. Christiansen NP, Haake RJ, Hurd DD. Early herpes zoster infection in adult patients with Hodgkin's disease undergoing autologous bone marrow transplant. Bone Marrow Transplant 1991;7:435-7.
13. Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation: Incidence, risk factors and complications. Bone Marrow Transplant 1994;13: 277-83.
14. Tyring S, Belanger R, Bezwoda W, Ljungman P, Boon R, Saltzman RL, for the Collaborative Famciclovir Immunocompromised Study Group. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest 2001;19:13-22.
15. Straus SE, Ostrove JM, Inchauspé G, Felser JM, Freifeld A, Croen KD, et al. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. Ann Intern Med 1988; 108:221-37.
16. Gershon AA, Steinberg SP, and the Varicella Vaccine Collaborative Study Group of the National Institute of Allergy and Infectious Diseases. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med 1989;320:892-97.
17. Hardy I, Gershon AA, Steinberg SP, LaRussa P, and the Varicella Vaccine Collaborative Study Group. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. N Engl J Med 1991;325: 1545-50.
18. Sauerbrei A, Prager J, Hengst U, Zintl F, Wutzler P. Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant 1997;20:381-3.
19. Redman RL, Nader S, Zerboni L, Liu C, Wong RM, Brown BW, et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 1997; 176:578-85.
20. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T lymphocyte response to cytomegalovirus following human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991;78:1373-80.
21. Reusser P, Attenhofer R, Hebart H, Helg C, Chapuis B, Einsele H. Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants. Blood 1997;89:3873-9.
22. Ljungman P, Lambertenghi Deliliers G, Platzbecker U, Matthes-Martin S, Bacigalupo A, Einsele H, et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. Blood 2001;97:388-92.
23. Boeckh M, Gooley TA, Reusser P, Buckner CD, Bowden RA. Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. J Infect Dis 1995;172:939-43.
24. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118:173-8.
25. Goodrich JM, Mori M, Gleaves CA, DuMond C, Cays M, Ebeling DF, et al. Prevention of cytomegalovirus disease after allogeneic marrow transplantation by early treatment with ganciclovir. N Engl J Med 1991;325:1601-7.
26. Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D, et al., for the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Randomized multicenter trial of foscarnet versus ganciclovir for pre-emptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002;99:1159-64.
27. Reusser P. Oral valganciclovir: A new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts. Expert Opin Investig Drugs 2001;10:1745-53. (Erratum: Expert Opin Investig Drugs 2002;11:733.
28. Englund JA, Zimmermann ME, Swierkosz EM, Goodmann JL, Scholl DR, Balfour HH Jr. Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann Intern Med 1990;112:416-22.
29. Reusser P. Herpesvirus resistance to antiviral drugs: A review of the mechanisms, clinical importance and therapeutic options. J Hosp Infect 1996;33:235-48.
30. Jabs DA, Enger C, Dunn JP, Forman M, for the CMV Retinitis and Viral Resistance Study Group. Cytomegalovirus retinitis and viral resistance: Ganciclovir resistance. J Infect Dis 1998;177:770-3.
31. Chakrabarti S, Pillay D, Ratcliffe D, Cane PA, Collingham KE, Milligan DW. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: Risk factors and prognostic significance. J Infect Dis 2000;181:2055-8.
32. Chen Y, Scieux C, Garrait V, Socié G, Rocha V, Molina J-M, et al. Resistant herpes simplex virus type 1 infection: An emerging concern after allogeneic stem cell transplantation. Clin Infect Dis 2000;31:927-35.
33. Eckle T, Prix L, Jahn G, Klingebiel T, Handgretinger R, Selle B, et al. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 2000;96:3286-9.
34. Boivin G, Gilbert C, Gaudreau A, Greenfield I, Sudlow R, Roberts NA. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J Infect Dis 2001;184:1598-602.
35. Raad I, Abbas J, Whimbey E. Infection control of nosocomial respiratory viral disease in the immunocompromised host. Am J Med 1997;102(Suppl 3A):48-52.
36. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2000;2:CD001269.